China Biosimilars Market Size, Industry Share And Growth in 2018

The global Biosimilars market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Get free request sample @ https://www.radiantinsights.com/research/china-biosimilars-industry-2018/request-sample?utm_source=Anurag&utm_campaign=Sharma

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Biosimilars development status and future trend in China, focuses on top players in China, also splits Biosimilars by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include

Pfizer

Sandoz International GmbH

Teva Pharmaceuticals Industries

Amgen Inc

Biocon

Dr. Reddy's Laboratories

F. Hoffmann-La Roche

Celltrion

Samsung Bioepis

Geographically, this report splits the China market into six regions,

South China

East China

Southwest China

Northeast China

North China

Central China

Northwest China

On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)

Peptides (Glucagon, Calcitonin)

Browse full report with TOC @ https://www.radiantinsights.com/research/china-biosimilars-industry-2018?utm_source=Anurag&utm_campaign=Sharma

On the basis of the end users/application, this report covers

Oncology

Blood Disorders